The short answer
Good embryos still fail often. Even a chromosomally tested (euploid) blastocyst led to a live birth in about 52–63% of single transfers in a large US series, depending on age 3. Chance is the first explanation. ESHRE and ASRM suggest a focused review after repeated failures: the uterine cavity, tubes, lining and transfer, not immune panels 1,2.
You were told the embryos were good. Perhaps they were graded AA or AB, perhaps one had tested chromosomally normal, perhaps the lining measured well on the day. The transfer still did not work, and it is natural to conclude that something hidden must be wrong with your body.
This page takes the three versions of that situation one at a time: good-grade embryos, a PGT-normal embryo, and a good lining. For each it sets out what the evidence says about chance, and then the shared workup that ESHRE's 2023 recommendations and ASRM's 2026 committee opinion on implantation failure support 1,2. It also lists what those bodies say is not worth paying for.
How common is this?
64.8%
Live birth per first frozen single euploid transfer at one US centre (4,429 women, mean age 35.4); 54.4% on the second and 54.1% on the third4
92.6%
Cumulative live birth after up to three consecutive single euploid transfers in the same US cohort4
82.0%
Positive pregnancy test per single euploid transfer, women under 35, in 8,175 US transfers; 73.3% above 423
56.4%
Share of blastocysts graded 'excellent' that tested chromosomally normal, in 956 biopsied blastocysts from women mostly over 35 or with past failures10
Reading your report
- Good-quality embryo
- An embryo whose appearance scored well on the lab's grading scale. It says nothing directly about chromosomes.
- Euploid / PGT-A normal
- A biopsy of a few outer cells showed the expected number of chromosomes. The HFEA notes the result is used to represent the whole embryo and can occasionally be wrong 11.
- Mosaic
- A PGT-A result suggesting a mix of cells with normal and abnormal chromosome numbers. The HFEA notes mosaic embryos may have a lower chance of pregnancy, though healthy births have been reported 11.
- Endometrial thickness (EMT)
- The thickness of the womb lining on scan before transfer, in millimetres. A 'good' number does not show whether the cavity has a polyp, fibroid or scarring.
- Hysteroscopy / 3D ultrasound / SHG
- Ways of looking at the inside of the uterus: a thin camera through the cervix, a three-dimensional scan, or a scan with saline in the cavity (sonohysterography).
- Hydrosalpinx
- A blocked fallopian tube filled with fluid, which is widely considered relevant to implantation failure 1.
- Chronic endometritis (CE)
- Low-grade inflammation of the womb lining, diagnosed by biopsy or hysteroscopy. ESHRE notes there is no standard plasma-cell count that defines it 1.
- APA / APS
- Antiphospholipid antibodies and antiphospholipid syndrome, an immune condition linked to blood clots and pregnancy loss.
Likely causes, most common first
| Cause | How you'd know | Test that tells you |
|---|---|---|
| A chromosome error in an embryo that looked good | You cannot tell from the grade. ASRM calls age-related aneuploidy the principal cause of implantation failure 2 | PGT-A in a future cycle, as a shared decision (ESHRE: can be considered in RIF) 1,2 |
| Chance, even with a euploid embryo | Between about 35% and 48% of single euploid transfers did not end in a live birth in two large US series, depending on age and transfer number 3,4 | None after one transfer; ask for your cumulative chance so far 1 |
| A polyp, submucosal fibroid, adhesions or septum in the cavity | Seen on 3D ultrasound, saline scan or hysteroscopy; not visible from lining thickness alone | Repeat cavity assessment (ASRM: reasonable in RIF; ESHRE: can be considered) 1,2 |
| Hydrosalpinx | Suspected on ultrasound | HSG or other tubal imaging if in doubt (ESHRE: can be considered) 1 |
| Adenomyosis or endometriosis | ASRM notes adenomyosis is present in up to 25% of infertile women and is common in RIF 2 | Imaging; ASRM says higher-quality studies are needed to guide diagnosis and treatment 2 |
| Chronic endometritis | Endometrial biopsy with plasma-cell staining; no standard definition 1,2 | Testing and antibiotics if found (ESHRE: can be considered) 1 |
| A difficult transfer | Noted in the transfer record: cervical stenosis, a tortuous canal, repeated catheter attempts | Review of transfer notes; a meta-analysis cited by ASRM found at least 24% relative reduction in clinical pregnancy with difficult transfers 2 |
| A balanced chromosomal change in either partner | Karyotype blood test; ESHRE puts the prevalence in RIF couples at about 2.1% 1 | Karyotyping both partners (ESHRE: can be considered) 1 |
What did not cause this
"My body rejected a good embryo"
The HFEA states that immune rejection of the fetus rarely, if ever, happens, and that blood NK cell tests give no useful information about pregnancy outcome 9. ESHRE does not recommend NK cell, cytokine or HLA-C testing for implantation failure 1.
"If the embryo was euploid, the failure must be my uterus"
In 8,175 single euploid transfers, live birth per transfer was 62.5% under 35 and 52.9% above 42 3. In a US cohort limited to women with an anatomically normal uterus, 35.2% of first euploid transfers still did not lead to a live birth 4.
"My lining was thick, so it cannot be the lining"
Thickness is one measurement. ESHRE cites a large study in which lining thickness did not predict implantation of euploid frozen blastocysts 1, and thickness says nothing about polyps, adhesions or a hydrosalpinx.
My embryos were graded good. Why didn't they implant?
Because a grade describes appearance, not chromosomes. In a two-centre study of 956 biopsied blastocysts from women mostly over 35, or with past failures or miscarriages, 56.4% of those graded excellent were chromosomally normal 10. The rest were not, despite looking their best.
ASRM's 2026 committee opinion calls age-related aneuploidy the principal cause of implantation failure, because aneuploid blastocysts have very limited potential to implant or lead to a birth 2. ESHRE adds that grading itself has limited reproducibility, especially between centres 1. An AA from one lab and an AA from another may not mean the same thing.
So after one or two failed transfers of good-grade, untested embryos, the embryo remains the likeliest explanation. That does not mean something is wrong with your eggs in particular. It is the expected pattern for embryos of any age, rising with age 2.
A PGT-normal (euploid) embryo failed. What does that tell me?
Less than it seems. In a US series of 8,175 frozen single euploid transfers, live birth per transfer was 62.5% under 35, 58.3% at 35–37, 56.0% at 38–40, 52.2% at 41–42 and 52.9% above 42 3. Put the other way, roughly 4 in 10 euploid transfers did not lead to a birth 3.
In another US cohort of 4,429 women with a normal uterine cavity, live birth was 64.8% on the first euploid transfer and 54.4% on the second; after up to three, 92.6% had a live birth 4. In the STAR trial, ongoing pregnancy per transfer in the PGT-A group was 50% 5. In the control arm of a large US trial of euploid transfers at standard timing, 61.9% of transfers led to a live birth 6.
PGT-A also has limits. The biopsy samples a few outer cells, and the HFEA notes the test can miss an abnormality or report one that isn't there 11. For these reasons ASRM's 2026 opinion suggests RIF should only be considered after 3–6 failed euploid transfers 2. ESHRE uses a 60% cumulative predicted chance as its threshold for investigation 1.
All these figures come from US or European centres. None are Indian. Ask your clinic for its own euploid live-birth rate per transfer for your age.
My lining looked good. Could the uterus still be the problem?
It can, but thickness is not the test for it. ESHRE's 2023 recommendations cite a large study concluding that lining thickness on transfer day did not predict implantation of euploid frozen blastocysts 1. A normal measurement is reassuring about one thing only.
What thickness cannot show is the shape of the cavity or what is in it. ASRM considers it reasonable to repeat the cavity and tubal assessment in RIF, by saline scan, hysteroscopy, HSG or 3D ultrasound, and to offer hysteroscopy to remove polyps and submucosal fibroids 2. ESHRE says hysteroscopy can be considered, especially when a scan suggests a problem 1.
Hysteroscopy for everyone is a different question. In the TROPHY trial of 702 women with two to four failed IVF cycles and no known uterine problem, live birth was 29% with and 29% without hysteroscopy 1.
What workup do ESHRE and ASRM suggest after repeated failures?
Both bodies start with a detailed review of your history and every cycle before any test 1,2. ESHRE suggests this once your cumulative predicted chance of implantation has passed 60% without a positive test 1. Where the two bodies differ, both views are given below.
- Uterine cavity and tubes: repeat 3D ultrasound, saline scan or hysteroscopy if not recently done; tubal imaging if a hydrosalpinx is suspected (ESHRE: can be considered; ASRM: reasonable) 1,2.
- Lining: re-measure thickness, and review the oestrogen regimen if it stays thin (ESHRE: recommended) 1.
- Chronic endometritis: testing, with antibiotics if confirmed (ESHRE: can be considered; ASRM: some observational support, no agreed definition) 1,2.
- Receptivity tests such as ERA: HFEA rates them red, meaning evidence suggests they may reduce effectiveness 7. In a double-blind trial of 767 patients with euploid embryos, live birth was 58.5% with receptivity-timed transfer and 61.9% with standard timing; that trial excluded RIF 6. ASRM finds insufficient evidence for routine ERA in RIF 2; ESHRE's add-ons group does not recommend current tests 8.
- Immune tests (NK cells, cytokines, HLA-C): not recommended by ESHRE 1. ASRM finds insufficient evidence for routine immune therapies 2.
- Antiphospholipid antibodies: ESHRE recommends testing if you have extra risk factors for clotting and says it can be considered without them 1. ASRM finds insufficient data for routine testing in RIF 2. Ask your doctor which applies to you.
- Inherited thrombophilia panels: ESHRE says testing is likely to have a very limited role and should focus mainly on women with a personal or family history of blood clots 1.
- Karyotype of both partners: can be considered; if a change is found, genetic counselling and PGT where relevant is recommended (ESHRE) 1,2.
- Transfer technique: ASRM recommends following its embryo-transfer guidance, including ultrasound guidance and a soft catheter 2. ESHRE found no studies of transfer-technique changes specifically in RIF 1.
- Lifestyle review for both partners: recommended by ESHRE 1. ASRM advises stopping smoking before treatment 2.
What if everything comes back normal?
Then you are in the most common group, and it is not a dead end. ESHRE cites a study in which half of patients with RIF had a live birth with ART within 5 years 1. ASRM's 2026 opinion says that if no clear, correctable cause is found after a detailed review, extensive testing is unnecessary and it is reasonable to proceed with further transfers, as many patients ultimately conceive 2.
Some failures after good embryos remain unexplained, and the honest position of both bodies is that research has not yet found the missing piece 1,2. ESHRE asks clinics to limit tests and treatments to those with a clear rationale and data suggesting benefit 1. A normal workup is a reason to be more careful about new add-ons, not less.
What's worth checking
- List every transfer: date, day 3 or day 5, grade, tested or untested, and your age at egg collection.
- Ask your clinic for its own live-birth rate per transfer for your age and embryo type.
- Ask for an estimate of your cumulative chance of implantation so far; ESHRE's threshold for investigation is 60% 1.
- If you had PGT-A, ask for the full report, including any mosaic or low-level results 11.
- Check when your uterine cavity was last assessed, and by which method.
- Ask whether a hydrosalpinx has been ruled out 1.
- Read your transfer notes for any mention of a difficult transfer 2.
- Tell your doctor about any personal or family history of blood clots 1.
- Before paying for ERA, NK cell tests or immune treatments, ask for the HFEA rating and ESHRE position 1,7.
What could change next cycle
8 options, by strength of evidence
- Good evidence it helps 1
- Mixed, or some groups only 3
- Not enough studies yet 1
- Evidence says it doesn't help 3
Ratings follow the evidence reviews cited beside each option, not our opinion.
- Another transfer without new tests, if no cause is foundGood evidence it helps
ASRM 2026: extensive testing unnecessary, reasonable to proceed 2; ESHRE: proceed below its 60% threshold 1.
- PGT-A for untested embryos after repeated failuresMixed, or some groups only
ESHRE: can be considered in RIF 1; ASRM: may be offered, but no evidence it raises live birth in RIF 2; HFEA: red for live birth 11.
- Hysteroscopy or repeat cavity imagingMixed, or some groups only
ESHRE: can be considered, especially if a scan suggests a problem; TROPHY found 29% vs 29% without known pathology 1. ASRM: reasonable in RIF 2.
- Antibiotics for confirmed chronic endometritisMixed, or some groups only
ESHRE: can be considered 1; ASRM: some observational evidence, diagnosis not standardised 2.
- ERA or other receptivity-timed transferEvidence says it doesn't help
HFEA: red 7; 58.5% vs 61.9% live birth in the largest trial 6; ASRM: insufficient evidence in RIF 2.
- Immune treatments (intralipid, IVIG, G-CSF)Evidence says it doesn't help
ESHRE: intralipid, IVIG and G-CSF not recommended in RIF 1; ASRM: insufficient evidence for routine use 2.
- Heparin without diagnosed antiphospholipid syndromeNot enough studies yet
ESHRE: not recommended to improve pregnancy in RIF 1; ASRM: insufficient evidence for routine anticoagulation 2.
- Endometrial scratchingEvidence says it doesn't help
ASRM 2026: not effective and not recommended in RIF 2; ESHRE: not recommended 1.
Questions to ask your doctor
- Given my age and every embryo transferred so far, what is my cumulative predicted chance of implantation, and have we passed ESHRE's 60% threshold 1?
- When was my uterine cavity last assessed, by which method, and should it be repeated?
- Was any of my transfers difficult, and would you change anything about the technique?
- If my embryo was euploid, what is your clinic's live-birth rate per euploid transfer for my age?
- For each test you suggest, what result would change what we do next?
- Is this test or treatment recommended by ESHRE or ASRM for my situation, or is it an add-on?
Questions people ask
How many euploid embryo transfers fail before it counts as recurrent implantation failure?
Can a PGT-A result be wrong?
Yes, occasionally. The HFEA notes that the test may miss an abnormality or detect one that isn't there, and that mosaic results complicate interpretation 11. A euploid result raises the odds per transfer; it does not settle them.
Should I switch to a gestational carrier after good embryos fail?
ASRM says a gestational carrier can be considered after several failed transfers 2. It does not set a number, so ask your doctor what the uterine workup has shown before weighing it.
Is it worth testing my husband after good embryos failed?
The scan found a polyp. Will removing it help?
Possibly, though the evidence is thinner than most people are told. ASRM's 2026 opinion says there is moderate evidence that endometrial polyps harm receptivity and implantation, and that one randomised trial showed higher pregnancy rates after polyp removal before intrauterine insemination, but that there is a lack of evidence that removing a polyp before IVF improves implantation or live birth 2.
I have a fibroid that is not inside the cavity. Does it need removing?
There is no clear answer yet. ASRM's 2026 opinion notes fair evidence that submucosal fibroids reduce implantation, while the role of intramural ones is less clear: a meta-analysis of 9,189 IVF cycles found non-cavity-distorting intramural fibroids reduced live birth (relative risk 0.82), mostly in retrospective studies, and ASRM states that evidence to guide treatment is still lacking 2.
My tube is blocked and full of fluid. Does it need removing before the next transfer?
This is one of the few things with clear trial support. A Cochrane review of 11 randomised trials in 1,386 women found that removing the tube probably increases clinical pregnancy compared with no surgery (risk ratio 2.02): from about 19% without surgery to between 27% and 52% with it 12. No trial in that comparison reported live birth, and the evidence on complications was very low quality 12.
My progesterone was low on the day of transfer. Could that be why?
Nobody can tell you that yet. ASRM's 2026 opinion reports one prospective study in which progesterone measured on transfer day was comparable between 86 women with repeated implantation failure and 37 controls, and concludes there are insufficient data to recommend any particular progesterone regimen for these patients 2. Ask what your clinic measures, when, and what it would change.
Is PRP or another lining treatment worth trying?
Not yet, on ASRM's reading. Its 2026 opinion notes that studies of platelet-rich plasma infused into the uterus in repeated implantation failure used widely varying definitions, differed in dose and timing, and mostly had no control group, and concludes there is insufficient evidence to support PRP in these patients 2. It says the same about routine immune therapies 2.
Would losing weight improve the chances next time?
It may help your pregnancy, but do not count on it changing this. ASRM's 2026 opinion says patients should be encouraged to reach a healthy weight before pregnancy, and that women should stop smoking before treatment, while noting that a study of women who gained or lost weight between two transfer cycles found no improvement in transfer success after weight loss 2.
Is anything actually known about why euploid embryos fail?
Some of it, not all. The systematic review that set out to open this 'black box' pooled 372 studies and found lower live birth linked to a reduced inner cell mass (odds ratio 0.37), poorer outer-layer quality (0.53), an overall grade below BB (0.40) and delayed development (0.56), plus a small effect of age 38 and over 13. The authors rate the evidence low or very low quality 13.
Could my embryo have been damaged when it was thawed?
It is possible, and your laboratory will know. The HFEA states that not all embryos survive freezing and warming, that very occasionally none do, and that embryos which do survive may lose a cell or two 14. Ask whether your embryo survived intact and how it looked immediately before transfer; the laboratory records this.
Sources
- ESHRE Working Group on Recurrent Implantation Failure; Cimadomo D, de los Santos MJ, Griesinger G, et al. ESHRE good practice recommendations on recurrent implantation failure. Hum Reprod Open. 2023;2023(3):hoad023. ESHRE / Human Reproduction Open
- Practice Committee of the American Society for Reproductive Medicine. Recurrent implantation failure: a committee opinion. Fertil Steril. 2026;126:277–293. ASRM
- Reig A, Franasiak J, Scott RT Jr, Seli E. The impact of age beyond ploidy: outcome data from 8175 euploid single embryo transfers. J Assist Reprod Genet. 2020;37(3):595–602. Journal of Assisted Reproduction and Genetics
- Pirtea P, De Ziegler D, Tao X, et al. Rate of true recurrent implantation failure is low: results of three successive frozen euploid single embryo transfers. Fertil Steril. 2021;115(1):45–53. Fertility and Sterility
- Munné S, Kaplan B, Frattarelli JL, et al; STAR Study Group. Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial. Fertil Steril. 2019;112(6):1071–1079.e7. Fertility and Sterility
- Doyle N, Jahandideh S, Hill MJ, Widra EA, Levy M, Devine K. Effect of timing by endometrial receptivity testing vs standard timing of frozen embryo transfer on live birth in patients undergoing in vitro fertilization: a randomized clinical trial. JAMA. 2022;328(21):2117–2125. JAMA
- Human Fertilisation and Embryology Authority. Endometrial receptivity testing (treatment add-on ratings). HFEA (UK regulator)
- ESHRE Add-ons working group; Lundin K, Bentzen JG, Bozdag G, et al. Good practice recommendations on add-ons in reproductive medicine. Hum Reprod. 2023;38(11):2062–2104. ESHRE / Human Reproduction
- Human Fertilisation and Embryology Authority. Immunological tests and treatments for fertility (treatment add-on information). HFEA (UK regulator)
- Capalbo A, Rienzi L, Cimadomo D, et al. Correlation between standard blastocyst morphology, euploidy and implantation: an observational study in two centers involving 956 screened blastocysts. Hum Reprod. 2014;29(6):1173–1181. Human Reproduction
- Human Fertilisation and Embryology Authority. Pre-implantation genetic testing for aneuploidy (PGT-A) (treatment add-on ratings). HFEA (UK regulator)
- Melo P, Georgiou EX, Johnson N, van Voorst SF, Strandell A, Mol BWJ, Becker C, Granne IE. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation. Cochrane Database Syst Rev. 2020;10(10):CD002125. Cochrane
- Cimadomo D, Rienzi L, Conforti A, et al. Opening the black box: why do euploid blastocysts fail to implant? A systematic review and meta-analysis. Hum Reprod Update. 2023;29(5):570-633. ESHRE / Human Reproduction Update
- Human Fertilisation and Embryology Authority. Embryo freezing (patient information page). HFEA (UK regulator)